Hepion Pharmaceuticals, Inc. HEPA OTC

Other OTC • Healthcare • Biotechnology • US • USD

SharesGrow Score

58/100

2/6 Pass

SharesGrow Intrinsic Value

SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

Hepion Pharmaceuticals, Inc. (HEPA) .

Criteria proven by this page:

VALUE (100/100, Pass) — analyst target implies upside (+145733.3%).
Analyst consensus target $70.00 (+145733.3% upside) — significant upside potential according to Wall Street analysts.

Overall SharesGrow Score: 56/100 with 2/7 criteria passed.

SharesGrow 7-Criteria Score

58/100

SG Score

View full scorecard →

✓

VALUE

100/100

Price-to-Earnings & upside

Proven by this page

FUTURE

52/100

Analyst consensus

→ Forecast

✗

PAST

0/100

→ Income

HEALTH

67/100

Debt-to-Equity & liquidity

→ Health

✗

MOAT

28/100

→ Income

✓

GROWTH

100/100

→ Income

—

INCOME

N/A

No coverage

Valuation Snapshot — HEPA

Valuation Multiples

P/E (TTM)0.0

Forward P/EN/A

PEG RatioN/A

Forward PEGN/A

P/B Ratio0.00

P/S Ratio0.00

EV/EBITDA0.0

Per Share Data

EPS (TTM)$-0.88

Book Value / Share$0.00

Revenue / Share$0.00

FCF / Share$0.00

Yields & Fair Value

Earnings YieldN/A

Dividend Yield0.00%

Analyst Target$70.00 (+145733.3%)

EPS: Actual vs Estimates

P/E Ratio & Earnings Yield

Earnings Per Share (EPS) History

Year	EPS (Diluted)	Revenue	Net Income	Net Margin
2016	$-2,859.26	$0.00	$-14.89M	-
2017	$0.00	$0.00	$-15.02M	-
2018	$0.00	$0.00	$-9.45M	-
2019	$0.00	$0.00	$-7.04M	-
2020	$0.00	$0.00	$-20.35M	-
2021	$-465.52	$0.00	$-32.72M	-
2022	$-594.75	$0.00	$-42.2M	-
2023	$-616.07	$0.00	$-48.93M	-
2024	$-107.35	$0.00	$-13.19M	-
2025	$-0.88	$0.00	$-8.28M	-